The FDA approval of Izervay has provided a second welcomed treatment option for geographic atrophy, with good efficacy and a favorable safety profile.
“It’s great news for our field as well as patients suffering from geographic atrophy,” Healio | OSN Retina/Vitreous Board Member Arshad M. Khanani, MD, MA, FASRS, said. “Geographic atrophy is a progressive, devastating disease that causes decline in vision and a loss of autonomy for numerous patients over time. It’s disheartening to witness some of my patients who had perfect vision a decade ago now facing legal